Sintilimab plus a bevacizumab biosimilar (IBI305) and chemotherapy prolonged the median PFS (6.9 vs. 4.3 months; p < 0.0001) and was well-tolerated in patients with EGFR-mutant NSCLC who progressed on previous EGFR-TKI therapy. Here, EGFR is linked to non-small cell lung carcinoma.